Skip to main content
. 2014 Jan 7;20(1):148–162. doi: 10.3748/wjg.v20.i1.148

Table 2.

Humoral and neutralizing antibody response

Antigen Control group
E6 group
E9 group
L6 group
L9 group
Week 0 Week 48 P value Week 0 Week 48 P value Week 0 Week 48 P value Week 0 Week 48 P value Week 0 Week 48 P value
Humoral response
Capsid IgM Seroc 96.1 96.1 - 100.0 100.0 - 100.0 100.0 - 100.0 100.0 - 100.0 100.0 -
Titer 108.9 ± 96.4 57.3 ± 81.9 0.002 269.3 ± 313.5 107.4 ± 105.3 0.003 210.8 ± 223.0 98.3 ± 104.2 0.008 310.5 ± 338.4 273.8 ± 530.7 ns 174.9 ± 182.5 170.7 ± 221.6 ns
IgA Seroc 84.6 73.1 ns 86.6 66.6 ns 86.6 86.6 - 92.8 85.7 ns 100.0 91.6 ns
Titer 12.0 ± 20.8 10.0 ± 16.2 0.020 48.2 ± 76.9 23.6 ± 26.6 0.010 38.3 ± 49.2 29.3 ± 34.4 ns 34.1 ± 38.5 24.8 ± 41.3 0.006 30.3 ± 25.6 22.9 ± 26.9 ns
IgG Seroc 96.1 96.1 - 100.0 100.0 - 100.0 100.0 - 100.0 100.0 - 91.6 91.6 -
Titer 30056.0 ± 39875.0 17913.7 ± 24413.0 < 0.001 49443.7 ± 40431.0 24135.7 ± 23793.0 0.002 30604.8 ± 22036.0 28932.5 ± 24813.0 ns 42400.4 ± 73634.0 31502.8 ± 62453.0 0.040 52700.6 ± 69336.1 33379.0 ± 52006.1 0.010
E2 IgM Seroc 34.6 19.2 ns 33.3 26.6 ns 13.3 13.3 ns 57.1 35.7 ns 25.0 33.3 ns
Titer 7.1 ± 3.5 9.7 ± 14.5 ns 7.8 ± 4.7 7.8 ± 2.4 ns 5.9 ± 2.0 5.9 ± 1.9 ns 8.7 ± 3.7 8.8 ± 5.5 ns 11.4 ± 19.1 9.4 ± 7.2 ns
IgA Seroc 15.3 11.5 ns 6.6 6.6 ns 6.6 0.0 - 14.2 0.0 - 0.0 0.0 -
Titer 5.8 ± 1.8 5.6 ± 1.6 ns 5.3 ± 1.3 5.3 ± 1.3 ns 5.3 ± 1.3 5.00 ± 0 ns 5.7 ± 1.8 5.0 ± 0 ns 5.0 ± 0.0 5.0 ± 0.0 ns
IgG Seroc 61.5 80.7 ns 46.4 66.6 ns 86.6 86.6 ns 71.4 71.4 ns 66.6 83.3 ns
Titer 325.9 ± 380.0 222.8 ± 221.0 ns 245.2 ± 355.0 176.5 ± 216 ns 611.8 ± 671.0 468.1 ± 707 ns 585.3 ± 1055.8 415.2 ± 644.8 ns 214.5 ± 306.4 159.4 ± 205.0 ns
NS3 IgM Seroc 92.3 84.6 ns 100.0 100.0 - 93.3 86.6 ns 100.0 92.8 ns 100.0 91.6 ns
Titer 171.0 ± 428.8 33.1 ± 43.9 < 0.001 211.1 ± 300.6 62.18 ± 69.55 0.003 55.7 ± 85.7 23.6 ± 14.2 0.040 94.7 ± 146.0 132.3 ± 334.7 ns 214.3 ± 297.3 110.6 ± 192.2 ns
IgA Seroc 76.9 50.0 0.008 66.6 60.0 ns 66.6 26.6 0.030 57.1 42.8 ns 83.3 75.0 ns
Titer 30.2 ± 87.6 24.1 ± 75.9 < 0.001 83.7 ± 240.4 16.3 ± 18.4 0.009 12.0 ± 7.7 8.2 ± 3.6 0.005 20.3 ± 31.8 19.8 ± 41.4 ns 47.8 ± 82.9 53.1 ± 100.2 ns
IgG Seroc 96.1 96.1 - 100.0 100.0 - 100.0 100.0 - 100.0 100.0 - 100.0 100.0 -
Titer 15907.0 ± 15723.0 9684.0 ± 12663.0 0.002 11881.0 ± 7195.0 6493.0 ± 5575.0 0.001 10695.0 ± 10046.4 5166.0 ± 5304.0 0.020 8135.0 ± 8076.2 4570.0 ± 5277.1 0.030 13893.1 ± 11677.0 8806.2 ± 8510.0 ns
Neutralizing antibody response
Positive (%) 46.2 46.7 ns 66.7 58.3 ns 35.7 14.3 ns 23.1 30.8 ns 41.7 41.7 ns
Infectivity (%) 71.0 ± 77.7 58.7 ± 26.6 ns 52.6 ± 24.7 51.0 ± 20.0 ns 61.7 ± 25.1 76.1 ± 22.8 ns 73.5 ± 29.4 60.8 ± 23.8 0.040 53.2 ± 26.5 53.2 ± 26.5 ns

Seroc: Seroconversion; ns: Not significant. Seroconversion data are presented as percent of samples with detectable antibody responses. Titer and infectivity data are presented as mean ± SD, except for IgA response against the capsid in the control group, which is presented as median ± rank. Statistical values refer to time dependent (week 0 vs week 48) differences in one group (McNemar test and paired t test or Wilcoxon signed rank test). Significant differences were considered for P < 0.05. Positive (%) refers to the percent of samples with detectable neutralizing antibody response. Infectivity (%) = (foci forming units in the presence of antibodies from a patient/foci forming unit in the absence of antibodies) × 100.